Impact News +++ Ad-hoc News: Gerresheimer AG (EQS) +++ GERRESHEIMER Aktie -4,16%

HIKMA Aktie

>HIKMA Aktienkurs

23 EUR -0.9% (Tradegate)

Ask: 23.2 EUR / 223 Stück

Bid: 23 EUR / 228 Stück

Tagesumsatz: 3 Stück

Realtime Kurs von 8 bis 22 Uhr!

HIKMA Aktie über LYNX handeln

Intraday

1 Jahr

>HIKMA Performance

1 Woche: -0,4%

1 Monat: -8,4%

3 Monate: +2,7%

6 Monate: -5,3%

1 Jahr: +4,1%

laufendes Jahr: -5,0%

>HIKMA Aktie

Name:

HIKMA PHARMACEUTIC.LS-,10

Land:

Großbritannien

Sektor:

Gesundheit

ISIN/ Wkn:

GB00B0LCW083 / A0HG69

Symbol/ Ticker:

H5P (Frankfurt)

Kürzel:

FRA:H5P, ETR:H5P, H5P:GR

Index:

FTSE100

Webseite:

http://www.hikma.com/

Marktkapitalisierung:

5550 Mio. EUR

Umsatz:

2746.69 Mio. EUR

EBITDA:

690.62 Mio. EUR

Gewinn je Aktie:

1.229 EUR

Schulden:

1149.57 Mio. EUR

Liquide Mittel:

186.92 Mio. EUR

Umsatz-/ Gewinnwachstum:

7.6% / 125.4%

KGV/ KGV lG:

17.93 / 12.87

KUV/ KBV/ PEG:

2.06 / 2.75 / 2.33

Gewinnm./ Eigenkapitalr.:

11.48% / 15.98%

Dividende je Aktie:

0.731 EUR

Dividendenrendite/ -schätzung:

2.9% / 2.82%

Div. Historie:

19.03.25 - 0.43868€
15.08.24 - 0.29191€

>weitere anzeigen...

Insiderhandel:

Suchwörter:

HIKMA

Letzte Datenerhebung:

16.07.25

>HIKMA Eigentümer

Aktien: 220.43 Mio. St.

f.h. Aktien: 153.35 Mio. St.

Insider Eigner: 30.39%

Instit. Eigner: 38.1%

Leerverk. Aktien: 1.19%

>HIKMA Peer Group

ANGLE PLC

ARECOR

CEL AI

CHILL BRANDS

GENFLOW

HVIVO

LIVANOVA

POOLBEG

ROYALTY PHARMA

SOLVONIS

>HIKMA Chart & Kurs - Tradegate

>HIKMA News

14.07.25 - 11:30	Hikma Pharma Announces Launch Of Morphine Sulfate Injection In The US (AFX)
	BRUSSELS/FRANKFURT/PARIS (dpa-AFX) - Hikma Pharmaceuticals has launched Morphine Sulfate Injection, USP, in 2mg/mL and 4mg/mL doses in the US. The product has been launched in a prefilled syringe ......

04.07.25 - 13:24	FDA approves Hikma’s Tyzavan for multiple infections (PBR)
	Tyzavan is indicated for the treatment of several serious infections in adults and children one month and above, including septicemia, infective endocarditis, skin and skin structure infections, bone The post FDA approves Hikma's Tyzavan for multiple infections appeared first on Pharmaceutical Business review....

02.07.25 - 14:48	Hikma Gets FDA Approval For TYZAVAN Vancomycin Injection (AFX)
	LONDON (dpa-AFX) - Hikma Pharmaceuticals PLC (HIK) Wednesday said that the US Food and Drug Administration (FDA) has approved TYZAVAN, a ready-to-infuse formulation of vancomycin.TYZAVAN is indica......

02.07.25 - 14:03	Hikma receives FDA approval for TYZAVAN™ (Vancomycin Injection, USP) in the US (PR Newswire)
	Ready-to-infuse sepsis therapy marks new advancement in time-critical treatment LONDON, July 2, 2025 /PRNewswire/ -- Hikma Pharmaceuticals PLC (Hikma), the multinational pharmaceutical company, today announced the approval of a novel formulation of the first-of-its-kind, ready-to-infuse......

30.06.25 - 11:01	UK pharma group Hikma ploughs $1bn into US manufacturing as tariff threat lingers (DailyMail)
	Britain's pharmaceutical sector still faces potential for further tariffs, as well as suggestions the White House could clamp down on the price of medicines in the US....

30.06.25 - 08:42	Hikma Pharmaceuticals to invest $1B by 2030 to expand US manufacturing, R&D (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

28.06.25 - 17:01	Hikma Pharmaceuticals USA announces $1 Billion of new US investment to further expand its domestic manufacturing and development of essential generic medicines (PR Newswire)
	Next phase builds on 34+ years of serving the needs of US patients and healthcare providers COLUMBUS, Ohio, June 28, 2025 /PRNewswire/ -- In its ongoing mission to help meet America's growing need for high-quality US-made medicines, Hikma Pharmaceuticals USA today announces it will invest......

10.06.25 - 13:06	DIRECTOR DEALINGS: Hikma exec and AB Dynamics advisor sell shares (Alliance)
	The following is a round-up of share dealings by London-listed company directors and managers announced so far this week and not separately reported by Alliance......

27.05.25 - 08:48	Bio-Thera Solutions And Hikma Pharma Say FDA Approved STARJEMZA Injection (AFX)
	LONDON (dpa-AFX) - Bio-Thera Solutions Ltd and Hikma Pharmaceuticals PLC announced that the U.S. Food and Drug Administration has approved STARJEMZA (ustekinumab-hmny) Injection, a biosimilar refe......

27.05.25 - 08:01	Bio-Thera Solutions and Hikma Pharmaceuticals announce FDA approval of STARJEMZA® (ustekinumab-hmny) Injection, a biosimilar referencing STELARA® (ustekinumab) Injection (PR Newswire)
	GUANGZHOU, China and LONDON, May 27, 2025 /PRNewswire/ -- Bio-Thera Solutions, Ltd (688177:SH), a commercial-stage biopharmaceutical company developing a pipeline of biosimilars and innovative assets and Hikma Pharmaceuticals PLC, along with its wholly owned subsidiary Hikma......

21.05.25 - 11:24	RBC Capital ups price target on Hikma (ShareCast)
	Um den gesamten Artikel unter news.google.com zu lesen, klicken Sie bitte auf die Überschrift...

21.05.25 - 11:24	Broker tips: Kingfisher, Accesso, Hikma (ShareCast)
	Um den gesamten Artikel unter news.google.com zu lesen, klicken Sie bitte auf die Überschrift...

16.05.25 - 15:12	FTSE 100 battles higher as defensive stocks sought, Aviva and Hikma make splash (Proactive Investors)
	Um den gesamten Artikel unter news.google.com zu lesen, klicken Sie bitte auf die Überschrift...

15.05.25 - 14:00	Hikma shares climb on new outlook, targets $5 billion sales by 2030 (Alliance)
	Hikma Pharmaceuticals PLC on Thursday unveiled new medium-term guidance forecasting high single-digit revenue and operating profit growth in the three years to 2027.The London-based pharmaceutical......

24.04.25 - 13:55	Hikma shares edge up on steady guidance (Investing.com)
	Um den gesamten Artikel unter investing.com zu lesen, klicken Sie bitte auf die Überschrift...

24.04.25 - 11:00	Hikma feels ′well-positioned′ despite geo-political challenges (Alliance)
	Hikma Pharmaceuticals PLC on Thursday said it will be 'agile' in its response to the evolving tariff backdrop as it reiterated its full-year outlook.In a......

24.04.25 - 09:12	Hikma Pharma Reaffirms FY25 Guidance Amid Strong Start (AFX)
	LONDON (dpa-AFX) - Hikma Pharmaceuticals Plc (HIK, HIK.L), on Thursday, reiterated its full-year guidance following a solid start to 2025, highlighting strong performance across its core business ......

17.04.25 - 20:24	Hikma acquires rights to generic version of Novartis′ Mekinist (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

17.04.25 - 19:12	Hikma acquires Novugen′s FDA-approved ANDA for trametinib (PR Newswire)
	LONDON, April 17, 2025 /PRNewswire/ -- Hikma Pharmaceuticals PLC (Hikma), the multinational pharmaceutical company, today announces it has acquired the FDA-approved Abbreviated New Drug Application (ANDA) for trametinib tablets from Novugen. Hikma also announces it has entered into a......

10.04.25 - 10:36	LONDON BROKER RATINGS: Jefferies raises Hikma Pharmaceutical to ′buy′ (Alliance)
	The following London-listed shares received analyst recommendations Thursday morning and on Wednesday:----------FTSE 100----------Bernstein cuts easyJet price target to 480 (600) pence - 'market-perform' ----------Bernstein cuts......

>weitere News anzeigen...

>Impressum >Über uns >Datenschutz >Financial Data & Solutions

>Behalte deine Investments mit realtime Kursen & News im Blick. Finde neue spannende Aktien! Registriere Dich und werde Mitglied!

Zitat des Tages: Vollkommene Politik besteht darin, niemals das letzte Motiv zu enthüllen. - Benjamin Disraeli

Partner: >Tradegate Börse | >Dukascopy | >Boersentreff- Partner

Börsentreff auf Facebook |

Börsentreff auf X |

Börsentreff auf Instagram